Mergers & Acquisitions ·
NewcelX enters binding term sheet to divest Mazindol portfolio for up to $55M in milestones
NCELNewcelX Ltd.
NewcelX Ltd. has entered into a binding term sheet with REA Holdings Inc. to divest its worldwide Mazindol asset portfolio (CVR assets). The transaction provides $500,000 in upfront consideration, consisting of $30,000 in cash and shares representing a 9.4% equity stake in REA Holdings. NewcelX is also eligible for up to $55 million in potential development, regulatory, and commercial milestone payments, plus tiered royalties ranging from 2% to 8% on global net sales. The deal remains subject to definitive documentation and customary closing conditions. This strategic divestiture allows NewcelX to focus on its core cell-therapy pipeline for Type 1 Diabetes while preserving potential value for CVR holders. NewcelX Ltd. is a biopharmaceutical company developing stem-cell-derived therapies for Type 1 Diabetes.